IVF Gonadotropin Dosing Assessment
The proposed regimen of 225 IU recombinant FSH plus 150 IU menotropin daily is NOT correct and significantly exceeds evidence-based recommendations for IVF ovarian stimulation.
Why This Regimen is Problematic
The total gonadotropin dose you've been prescribed is 375 IU daily (225 IU rFSH + 150 IU menotropin), which is excessive and potentially dangerous. According to FDA labeling for menotropin, the recommended initial dose for IVF is 225 IU total daily, not 375 IU 1. The FDA explicitly states that daily doses should not exceed 450 IU, and your proposed regimen approaches this maximum from day one without any assessment of ovarian response 1.
Evidence-Based Starting Dose
The correct approach is to start with 225 IU total gonadotropin daily, which can be:
- 225 IU recombinant FSH alone, OR
- 150 IU menotropin + 75 IU recombinant FSH, OR
- 75 IU menotropin + 150 IU recombinant FSH
The FDA drug label is explicit that when combining menotropin with recombinant FSH, only the total starting dose of 225 IU has been studied in clinical trials 1.
Dose Adjustment Protocol
After starting at 225 IU total daily:
- Wait at least 5 days before making any dose adjustments
- Adjust based on ultrasound follicular development and serum estradiol levels
- Do not increase by more than 150 IU at each adjustment
- Do not adjust more frequently than every 2 days
- Never exceed 450 IU total daily
- Limit treatment duration to 20 days maximum
Safety Concerns with Your Proposed Regimen
Starting with 375 IU daily dramatically increases risks of:
Multiple pregnancy: Higher gonadotropin doses increase multifollicular development without improving pregnancy rates. Guidelines specifically recommend ≤75 IU when gonadotropins are used to minimize multiple pregnancy risk 2.
Ovarian hyperstimulation syndrome (OHSS): Excessive stimulation is the primary cause of OHSS, a potentially life-threatening complication 1.
Unnecessary medication exposure and cost: Research demonstrates that 150 IU versus 250 IU daily doses yield similar oocyte numbers and pregnancy rates in women aged 30-39 years 3. Even comparing 150 IU versus 225 IU, the higher dose only benefits women ≤32 years, with no advantage in older women 4.
Clinical Evidence Supporting Lower Doses
Multiple high-quality studies demonstrate that starting doses above 225 IU provide minimal benefit:
A randomized trial comparing 150 IU versus 250 IU daily rFSH found similar oocyte yields (8.9 vs 10.2), implantation rates (10.0% vs 10.9%), and pregnancy rates (17.1% vs 16.7%), but the higher dose required 903 IU more medication 3.
Another trial showed 225 IU was only superior to 150 IU in women ≤32 years; in women ≥33 years, both doses yielded similar results 4.
Correct Recommendation
Request your physician revise the protocol to start with 225 IU total daily gonadotropin (not 375 IU). The specific combination of menotropin and recombinant FSH can be discussed, but the total must not exceed 225 IU initially. Dose escalation should only occur after day 5, based on your individual ovarian response, and should follow the FDA-approved adjustment protocol 1.
The combination of FSH and LH activity (from menotropin) may have benefits for certain patients 5, 6, 7, but this does not justify exceeding the evidence-based total starting dose of 225 IU.